Keyword: Tecfidera

Biogen has been working hard to build out its pipeline, but as that effort plays out, the biotech faces a new patent challenge to its top moneymaker.

After releasing strong earnings, Biogen's executives did their best to reassure analysts that the success of the pipeline won't rely solely on Alzheimer's.

MyHealthTeams specialized social networks are adding pharma-sponsored resource centers with its most recent in spondyloarthritis.

Biogen grew sales 9% in the second quarter, beating Street expectations, but analysts on the company's conference call were focused elsewhere.

A patent ruling for Novartis will give Celgene time to secure FDA approval for its Gilenya rival and persuade physicians that it's a safer MS pill.

NICE is now endorsing Ocrevus for NHS coverage in relapsing-remitting MS and will deliver a decision on the primary progressive form soon.

Top drugmakers made more trips to the courthouse last year, aiming to blockade big-selling drugs against generic competitors.

Roche says it's in the midst of one of the most successful multiple sclerosis launches ever—and MS has had some doozies.

Celgene's MS candidate ozanimod might have challenged some big blockbusters in the field, but an FDA decision means it won't happen anytime soon.

Biogen boosted the stickers on some of its key MS medications Monday, and the payoff could make up for sales lost to new rivals.